Middle East & Africa Generic Drugs Market Size and Forecast (2021 - 2031) Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Molecule Type (Antidepressants, Antihistamines, Analgesics, Antibiotics, Antivirals, Diuretics, and Other Molecule Types), Indication (Metabolic Diseases, Cancer, Immunology, Respiratory Disorder, Cardiovascular Disorder, Neurology Disorder, Rare Diseases, and Other Indications), Type (Prescription and OTC Drugs), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
The Middle East and Africa (MEA) generic drugs market is poised for substantial growth, with projections indicating that the market size will reach approximately US$ 35,795.50 million by 2031, up from US$ 28,684.12 million in 2024. This growth trajectory reflects a compound annual growth rate (CAGR) of 3.2% from 2025 to 2031.
Executive Summary and Market Analysis
The MEA generic drugs market is being propelled by several key factors, including advancements in healthcare infrastructure, a growing demand for affordable treatment options, and an increasing prevalence of chronic diseases such as diabetes, cardiovascular disorders, cancer, and infectious diseases like malaria, HIV/AIDS, and tuberculosis. Countries such as Saudi Arabia, the UAE, and South Africa are particularly witnessing a surge in demand for generic drugs, driven by an aging population and rising life expectancy. According to the Ageing in the Middle East and North Africa report, the elderly demographic is expected to become the largest age group by 2050 in the MENA region.
Government initiatives aimed at promoting cost-effective healthcare solutions, centralized drug procurement, and price control policies are further facilitating the adoption of generic drugs across the region. Local pharmaceutical manufacturing is on the rise in countries like Egypt, Jordan, and South Africa, which helps to reduce dependency on imports and enhances regional drug security. Additionally, international collaborations and public-private partnerships are fostering innovation and the production of complex generics and biosimilars, positioning the MEA region as a significant player in the global generic pharmaceuticals market.
The increasing awareness of preventive healthcare and the expansion of health insurance schemes are also contributing to improved accessibility to medications. Regulatory reforms and expedited drug approval processes are enabling quicker market entry for generic drug manufacturers. Companies are investing in digital transformation, logistics infrastructure, and cold chain networks to enhance last-mile delivery and ensure product quality.
Market Segmentation Analysis
The MEA generic drugs market can be segmented based on molecule type, indication, type, and distribution channel:
The expiration of patents on branded drugs is a significant driver of the generic drug market. After patent expiration, generic manufacturers can produce and sell bioequivalent versions at lower prices, creating vast opportunities. Notable drugs set to lose their patents in the near future include Keytruda (Merck), Ozempic (Novo Nordisk), and several others, which collectively generated substantial revenue and will open avenues for generic alternatives.
Several blockbuster drugs are expected to lose their patents in 2024, including:
Country Insights
In terms of country-specific insights, the MEA generic drugs market includes key players from Saudi Arabia, South Africa, the UAE, and other regions. South Africa currently holds the largest market share, driven by healthcare reforms, government initiatives, and a pressing need for affordable medication. The country’s healthcare expenditure is approximately 8.5% of its GDP, with a significant portion allocated to generic drugs, reflecting a strong preference for cost-effective treatment options.
The South African government is actively promoting the use of generics through initiatives like the National Health Insurance scheme, which aims to reduce pharmaceutical costs. The local market is also supported by increasing partnerships between international pharmaceutical companies and local manufacturers to enhance the availability of generic drugs.
Company Profiles
Key players in the MEA generic drugs market include Teva Pharmaceutical Industries Ltd, Viatris Inc, Dr. Reddy's Laboratories Ltd, Novartis AG, Sun Pharmaceutical Industries Ltd, AbbVie Inc, AstraZeneca Plc, Sanofi SA, Aurobindo Pharma Ltd, and Glenmark Pharmaceuticals Ltd. These companies are employing various strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence and offer innovative products to consumers.
Executive Summary and Market Analysis
The MEA generic drugs market is being propelled by several key factors, including advancements in healthcare infrastructure, a growing demand for affordable treatment options, and an increasing prevalence of chronic diseases such as diabetes, cardiovascular disorders, cancer, and infectious diseases like malaria, HIV/AIDS, and tuberculosis. Countries such as Saudi Arabia, the UAE, and South Africa are particularly witnessing a surge in demand for generic drugs, driven by an aging population and rising life expectancy. According to the Ageing in the Middle East and North Africa report, the elderly demographic is expected to become the largest age group by 2050 in the MENA region.
Government initiatives aimed at promoting cost-effective healthcare solutions, centralized drug procurement, and price control policies are further facilitating the adoption of generic drugs across the region. Local pharmaceutical manufacturing is on the rise in countries like Egypt, Jordan, and South Africa, which helps to reduce dependency on imports and enhances regional drug security. Additionally, international collaborations and public-private partnerships are fostering innovation and the production of complex generics and biosimilars, positioning the MEA region as a significant player in the global generic pharmaceuticals market.
The increasing awareness of preventive healthcare and the expansion of health insurance schemes are also contributing to improved accessibility to medications. Regulatory reforms and expedited drug approval processes are enabling quicker market entry for generic drug manufacturers. Companies are investing in digital transformation, logistics infrastructure, and cold chain networks to enhance last-mile delivery and ensure product quality.
Market Segmentation Analysis
The MEA generic drugs market can be segmented based on molecule type, indication, type, and distribution channel:
- Molecule Type: The market is divided into categories such as antidepressants, antihistamines, analgesics, antibiotics, antivirals, diuretics, and others. The antibiotics segment is expected to hold the largest market share in 2024.
- Indication: The market is segmented into metabolic diseases, cancer, immunology, respiratory disorders, cardiovascular disorders, neurology disorders, rare diseases, and others. The cancer segment is projected to dominate the market in 2024.
- Type: The market is bifurcated into prescription and over-the-counter (OTC) drugs, with the prescription segment anticipated to hold a larger share in 2024.
- Distribution Channel: The market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies, with hospital pharmacies expected to lead in market share in 2024.
The expiration of patents on branded drugs is a significant driver of the generic drug market. After patent expiration, generic manufacturers can produce and sell bioequivalent versions at lower prices, creating vast opportunities. Notable drugs set to lose their patents in the near future include Keytruda (Merck), Ozempic (Novo Nordisk), and several others, which collectively generated substantial revenue and will open avenues for generic alternatives.
Several blockbuster drugs are expected to lose their patents in 2024, including:
- Abilify Maintena (Otsuka Pharmaceutical) - an injectable antipsychotic with US$ 15.5 billion in sales in 2022.
- Xarelto (Janssen Pharmaceuticals) - a leading anticoagulant.
- Farxiga (AstraZeneca) - an anti-diabetic drug generating approximately US$ 4.3 billion annually.
- Lynparza (AstraZeneca) - used in cancer treatment.
- Symbicort (AstraZeneca) - a respiratory drug.
- Entresto (Novartis) - a heart failure treatment.
- Latuda (Sunovion Pharmaceuticals) - an antipsychotic.
- Xifaxan (Salix Pharmaceuticals) - a gastrointestinal drug.
- Cabometyx (Exelixis) - used for advanced renal cell carcinoma.
Country Insights
In terms of country-specific insights, the MEA generic drugs market includes key players from Saudi Arabia, South Africa, the UAE, and other regions. South Africa currently holds the largest market share, driven by healthcare reforms, government initiatives, and a pressing need for affordable medication. The country’s healthcare expenditure is approximately 8.5% of its GDP, with a significant portion allocated to generic drugs, reflecting a strong preference for cost-effective treatment options.
The South African government is actively promoting the use of generics through initiatives like the National Health Insurance scheme, which aims to reduce pharmaceutical costs. The local market is also supported by increasing partnerships between international pharmaceutical companies and local manufacturers to enhance the availability of generic drugs.
Company Profiles
Key players in the MEA generic drugs market include Teva Pharmaceutical Industries Ltd, Viatris Inc, Dr. Reddy's Laboratories Ltd, Novartis AG, Sun Pharmaceutical Industries Ltd, AbbVie Inc, AstraZeneca Plc, Sanofi SA, Aurobindo Pharma Ltd, and Glenmark Pharmaceuticals Ltd. These companies are employing various strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence and offer innovative products to consumers.
1. INTRODUCTION
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:
4. MIDDLE EAST & AFRICA GENERIC DRUGS MARKET LANDSCAPE
4.1 Overview
4.2 PEST Analysis
4.2.1 Middle East & Africa
4.2.1.1 Saudi Arabia
4.2.1.2 South Africa
4.2.1.3 United Arab Emirates (UAE)
4.3 Top 10 Blockbuster Drugs Facing Patent Expiry in the Next 5 Years with Revenue Data and Market Impact:
4.4 Average Selling Price, 2024
4.5 Pipeline Analysis:
5. MIDDLE EAST & AFRICA GENERIC DRUGS MARKET – KEY MARKET DYNAMICS
5.1 Middle East & Africa Generic Drugs Market – Key Market Dynamics
5.2 Market Drivers
5.2.1 Patent Expiry and Loss of Market Exclusivity:
5.2.2 Government Policies and Regulatory Support for Generics
5.3 Market Restraints
5.3.1 Intense Price Competition and Thin Profit Margins
5.4 Market Opportunities
5.4.1 Increasing Government Initiatives to promote the use of generic drugs
5.5 Future Trends
5.5.1 Rising Popularity of Biosimilars in the Global Generic Drugs Market
5.6 Impact of Drivers and Restraints:
6. GENERIC DRUGS MARKET – MIDDLE EAST & AFRICA ANALYSIS
6.1 Middle East & Africa Generic Drugs Market Revenue (US$ Billion), 2021–2031
6.2 Middle East & Africa Generic Drugs Market Forecast Analysis
7. MIDDLE EAST & AFRICA GENERIC DRUGS MARKET ANALYSIS – BY MOLECULE TYPE
7.1 Antidepressants
7.1.1 Overview
7.1.2 Antidepressants: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
7.2 Antihistamines
7.2.1 Overview
7.2.2 Antihistamines: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
7.3 Analgesics
7.3.1 Overview
7.3.2 Analgesics: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
7.4 Antibiotics
7.4.1 Overview
7.4.2 Antibiotics: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
7.5 Antivirals
7.5.1 Overview
7.5.2 Antivirals: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
7.6 Diuretics
7.6.1 Overview
7.6.2 Diuretics: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
7.7 Others
7.7.1 Overview
7.7.2 Others: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8. MIDDLE EAST & AFRICA GENERIC DRUGS MARKET ANALYSIS – BY INDICATION
8.1 Metabolic Diseases
8.1.1 Overview
8.1.2 Metabolic Diseases: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.2 Cancer
8.2.1 Overview
8.2.2 Cancer: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.3 Immunology
8.3.1 Overview
8.3.2 Immunology: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.4 Respiratory Disorder
8.4.1 Overview
8.4.2 Respiratory Disorder: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.5 Cardiovascular Disorder
8.5.1 Overview
8.5.2 Cardiovascular Disorder: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.6 Neurology Disorder
8.6.1 Overview
8.6.2 Neurology Disorder: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.7 Rare Disease
8.7.1 Overview
8.7.2 Rare Disease: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.8 Others
8.8.1 Overview
8.8.2 Others: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
9. MIDDLE EAST & AFRICA GENERIC DRUGS MARKET ANALYSIS – BY TYPE
9.1 Prescription
9.1.1 Overview
9.1.2 Prescription: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
9.2 OTC Drugs
9.2.1 Overview
9.2.2 OTC Drugs: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
10. MIDDLE EAST & AFRICA GENERIC DRUGS MARKET ANALYSIS – BY DISTRIBUTION CHANNEL
10.1 Hospital Pharmacies
10.1.1 Overview
10.1.2 Hospital Pharmacies: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
10.2 Retail Pharmacies
10.2.1 Overview
10.2.2 Retail Pharmacies: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
10.3 Online Pharmacies
10.3.1 Overview
10.3.2 Online Pharmacies: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
11. MIDDLE EAST & AFRICA GENERIC DRUGS MARKET – COUNTRY ANALYSIS
11.1 Middle East & Africa
11.1.1 Middle East & Africa Generic Drugs Market – Revenue and Forecast Analysis – by Country
11.1.1.1 Middle East & Africa Generic Drugs Market – Revenue and Forecast Analysis – by Country
11.1.1.2 Saudi Arabia: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
11.1.1.2.1 Saudi Arabia: Middle East & Africa Generic Drugs Market Share – by Molecule Type
11.1.1.2.2 Saudi Arabia: Middle East & Africa Generic Drugs Market Share – by Indication
11.1.1.2.3 Saudi Arabia: Middle East & Africa Generic Drugs Market Share – by Type
11.1.1.2.4 Saudi Arabia: Middle East & Africa Generic Drugs Market Share – by Distribution Channel
11.1.1.3 South Africa: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
11.1.1.3.1 South Africa: Middle East & Africa Generic Drugs Market Share – by Molecule Type
11.1.1.3.2 South Africa: Middle East & Africa Generic Drugs Market Share – by Indication
11.1.1.3.3 South Africa: Middle East & Africa Generic Drugs Market Share – by Type
11.1.1.3.4 South Africa: Middle East & Africa Generic Drugs Market Share – by Distribution Channel
11.1.1.4 United Arab Emirates: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
11.1.1.4.1 United Arab Emirates: Middle East & Africa Generic Drugs Market Share – by Molecule Type
11.1.1.4.2 United Arab Emirates: Middle East & Africa Generic Drugs Market Share – by Indication
11.1.1.4.3 United Arab Emirates: Middle East & Africa Generic Drugs Market Share – by Type
11.1.1.4.4 United Arab Emirates: Middle East & Africa Generic Drugs Market Share – by Distribution Channel
11.1.1.5 Rest of Middle East & Africa: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
11.1.1.5.1 Rest of Middle East & Africa: Middle East & Africa Generic Drugs Market Share – by Molecule Type
11.1.1.5.2 Rest of Middle East & Africa: Middle East & Africa Generic Drugs Market Share – by Indication
11.1.1.5.3 Rest of Middle East & Africa: Middle East & Africa Generic Drugs Market Share – by Type
11.1.1.5.4 Rest of Middle East & Africa: Middle East & Africa Generic Drugs Market Share – by Distribution Channel
12. INDUSTRY LANDSCAPE
12.1 Overview
12.2 Expansion
12.3 New Product Development/ Launch/ Approvals
12.4 Merger and Acquisition/Partnership
12.5 Other Business Strategies
13. COMPANY PROFILES
13.1 Teva Pharmaceutical Industries Ltd
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Viatris Inc
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Dr. Reddy's Laboratories Ltd
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Novartis AG
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Sun Pharmaceutical Industries Ltd
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 AbbVie Inc
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 AstraZeneca Plc
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Sanofi SA
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 Aurobindo Pharma Ltd
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Glenmark Pharmaceuticals Ltd
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. APPENDIX
14.1 Glossary of Terms
14.2 About The Insight Partners
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:
4. MIDDLE EAST & AFRICA GENERIC DRUGS MARKET LANDSCAPE
4.1 Overview
4.2 PEST Analysis
4.2.1 Middle East & Africa
4.2.1.1 Saudi Arabia
4.2.1.2 South Africa
4.2.1.3 United Arab Emirates (UAE)
4.3 Top 10 Blockbuster Drugs Facing Patent Expiry in the Next 5 Years with Revenue Data and Market Impact:
4.4 Average Selling Price, 2024
4.5 Pipeline Analysis:
5. MIDDLE EAST & AFRICA GENERIC DRUGS MARKET – KEY MARKET DYNAMICS
5.1 Middle East & Africa Generic Drugs Market – Key Market Dynamics
5.2 Market Drivers
5.2.1 Patent Expiry and Loss of Market Exclusivity:
5.2.2 Government Policies and Regulatory Support for Generics
5.3 Market Restraints
5.3.1 Intense Price Competition and Thin Profit Margins
5.4 Market Opportunities
5.4.1 Increasing Government Initiatives to promote the use of generic drugs
5.5 Future Trends
5.5.1 Rising Popularity of Biosimilars in the Global Generic Drugs Market
5.6 Impact of Drivers and Restraints:
6. GENERIC DRUGS MARKET – MIDDLE EAST & AFRICA ANALYSIS
6.1 Middle East & Africa Generic Drugs Market Revenue (US$ Billion), 2021–2031
6.2 Middle East & Africa Generic Drugs Market Forecast Analysis
7. MIDDLE EAST & AFRICA GENERIC DRUGS MARKET ANALYSIS – BY MOLECULE TYPE
7.1 Antidepressants
7.1.1 Overview
7.1.2 Antidepressants: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
7.2 Antihistamines
7.2.1 Overview
7.2.2 Antihistamines: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
7.3 Analgesics
7.3.1 Overview
7.3.2 Analgesics: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
7.4 Antibiotics
7.4.1 Overview
7.4.2 Antibiotics: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
7.5 Antivirals
7.5.1 Overview
7.5.2 Antivirals: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
7.6 Diuretics
7.6.1 Overview
7.6.2 Diuretics: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
7.7 Others
7.7.1 Overview
7.7.2 Others: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8. MIDDLE EAST & AFRICA GENERIC DRUGS MARKET ANALYSIS – BY INDICATION
8.1 Metabolic Diseases
8.1.1 Overview
8.1.2 Metabolic Diseases: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.2 Cancer
8.2.1 Overview
8.2.2 Cancer: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.3 Immunology
8.3.1 Overview
8.3.2 Immunology: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.4 Respiratory Disorder
8.4.1 Overview
8.4.2 Respiratory Disorder: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.5 Cardiovascular Disorder
8.5.1 Overview
8.5.2 Cardiovascular Disorder: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.6 Neurology Disorder
8.6.1 Overview
8.6.2 Neurology Disorder: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.7 Rare Disease
8.7.1 Overview
8.7.2 Rare Disease: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.8 Others
8.8.1 Overview
8.8.2 Others: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
9. MIDDLE EAST & AFRICA GENERIC DRUGS MARKET ANALYSIS – BY TYPE
9.1 Prescription
9.1.1 Overview
9.1.2 Prescription: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
9.2 OTC Drugs
9.2.1 Overview
9.2.2 OTC Drugs: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
10. MIDDLE EAST & AFRICA GENERIC DRUGS MARKET ANALYSIS – BY DISTRIBUTION CHANNEL
10.1 Hospital Pharmacies
10.1.1 Overview
10.1.2 Hospital Pharmacies: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
10.2 Retail Pharmacies
10.2.1 Overview
10.2.2 Retail Pharmacies: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
10.3 Online Pharmacies
10.3.1 Overview
10.3.2 Online Pharmacies: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
11. MIDDLE EAST & AFRICA GENERIC DRUGS MARKET – COUNTRY ANALYSIS
11.1 Middle East & Africa
11.1.1 Middle East & Africa Generic Drugs Market – Revenue and Forecast Analysis – by Country
11.1.1.1 Middle East & Africa Generic Drugs Market – Revenue and Forecast Analysis – by Country
11.1.1.2 Saudi Arabia: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
11.1.1.2.1 Saudi Arabia: Middle East & Africa Generic Drugs Market Share – by Molecule Type
11.1.1.2.2 Saudi Arabia: Middle East & Africa Generic Drugs Market Share – by Indication
11.1.1.2.3 Saudi Arabia: Middle East & Africa Generic Drugs Market Share – by Type
11.1.1.2.4 Saudi Arabia: Middle East & Africa Generic Drugs Market Share – by Distribution Channel
11.1.1.3 South Africa: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
11.1.1.3.1 South Africa: Middle East & Africa Generic Drugs Market Share – by Molecule Type
11.1.1.3.2 South Africa: Middle East & Africa Generic Drugs Market Share – by Indication
11.1.1.3.3 South Africa: Middle East & Africa Generic Drugs Market Share – by Type
11.1.1.3.4 South Africa: Middle East & Africa Generic Drugs Market Share – by Distribution Channel
11.1.1.4 United Arab Emirates: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
11.1.1.4.1 United Arab Emirates: Middle East & Africa Generic Drugs Market Share – by Molecule Type
11.1.1.4.2 United Arab Emirates: Middle East & Africa Generic Drugs Market Share – by Indication
11.1.1.4.3 United Arab Emirates: Middle East & Africa Generic Drugs Market Share – by Type
11.1.1.4.4 United Arab Emirates: Middle East & Africa Generic Drugs Market Share – by Distribution Channel
11.1.1.5 Rest of Middle East & Africa: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
11.1.1.5.1 Rest of Middle East & Africa: Middle East & Africa Generic Drugs Market Share – by Molecule Type
11.1.1.5.2 Rest of Middle East & Africa: Middle East & Africa Generic Drugs Market Share – by Indication
11.1.1.5.3 Rest of Middle East & Africa: Middle East & Africa Generic Drugs Market Share – by Type
11.1.1.5.4 Rest of Middle East & Africa: Middle East & Africa Generic Drugs Market Share – by Distribution Channel
12. INDUSTRY LANDSCAPE
12.1 Overview
12.2 Expansion
12.3 New Product Development/ Launch/ Approvals
12.4 Merger and Acquisition/Partnership
12.5 Other Business Strategies
13. COMPANY PROFILES
13.1 Teva Pharmaceutical Industries Ltd
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Viatris Inc
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Dr. Reddy's Laboratories Ltd
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Novartis AG
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Sun Pharmaceutical Industries Ltd
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 AbbVie Inc
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 AstraZeneca Plc
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Sanofi SA
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 Aurobindo Pharma Ltd
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Glenmark Pharmaceuticals Ltd
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. APPENDIX
14.1 Glossary of Terms
14.2 About The Insight Partners
LIST OF TABLES
Table 1. Middle East & Africa Generic Drugs Market Segmentation
Table 2. Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Table 3. Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Molecule Type
Table 4. Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Indication
Table 5. Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Type
Table 6. Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Distribution Channel
Table 7. Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Country
Table 8. Saudi Arabia: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type
Table 9. Saudi Arabia: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication
Table 10. Saudi Arabia: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type
Table 11. Saudi Arabia: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel
Table 12. South Africa: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type
Table 13. South Africa: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication
Table 14. South Africa: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type
Table 15. South Africa: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel
Table 16. United Arab Emirates: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type
Table 17. United Arab Emirates: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication
Table 18. United Arab Emirates: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type
Table 19. United Arab Emirates: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel
Table 20. Rest of Middle East & Africa: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type
Table 21. Rest of Middle East & Africa: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication
Table 22. Rest of Middle East & Africa: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type
Table 23. Rest of Middle East & Africa: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel
Table 24. Glossary of Terms, Generic Drugs Market
Table 1. Middle East & Africa Generic Drugs Market Segmentation
Table 2. Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Table 3. Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Molecule Type
Table 4. Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Indication
Table 5. Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Type
Table 6. Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Distribution Channel
Table 7. Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Country
Table 8. Saudi Arabia: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type
Table 9. Saudi Arabia: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication
Table 10. Saudi Arabia: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type
Table 11. Saudi Arabia: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel
Table 12. South Africa: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type
Table 13. South Africa: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication
Table 14. South Africa: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type
Table 15. South Africa: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel
Table 16. United Arab Emirates: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type
Table 17. United Arab Emirates: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication
Table 18. United Arab Emirates: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type
Table 19. United Arab Emirates: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel
Table 20. Rest of Middle East & Africa: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type
Table 21. Rest of Middle East & Africa: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication
Table 22. Rest of Middle East & Africa: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type
Table 23. Rest of Middle East & Africa: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel
Table 24. Glossary of Terms, Generic Drugs Market
LIST OF FIGURES
Figure 1. Middle East & Africa Generic Drugs Market Segmentation – Country
Figure 2. PEST Analysis
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Middle East & Africa Generic Drugs Market Revenue (US$ Billion), 2021–2031
Figure 5. Middle East & Africa Generic Drugs Market Share (%) – by Molecule Type (2024 and 2031)
Figure 6. Antidepressants: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 7. Antihistamines: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 8. Analgesics: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 9. Antibiotics: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 10. Antivirals: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 11. Diuretics: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 12. Others: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 13. Middle East & Africa Generic Drugs Market Share (%) – by Indication (2024 and 2031)
Figure 14. Metabolic Diseases: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 15. Cancer: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 16. Immunology: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 17. Respiratory Disorder: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 18. Cardiovascular Disorder: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 19. Neurology Disorder: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 20. Rare Disease: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 21. Others: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 22. Middle East & Africa Generic Drugs Market Share (%) – by Type (2024 and 2031)
Figure 23. Prescription: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 24. OTC Drugs: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 25. Middle East & Africa Generic Drugs Market Share (%) – by Distribution Channel (2024 and 2031)
Figure 26. Hospital Pharmacies: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 27. Retail Pharmacies: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 28. Online Pharmacies: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 29. Middle East & Africa Generic Drugs Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 30. Saudi Arabia: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021– 2031 (US$ Billion)
Figure 31. South Africa: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021– 2031 (US$ Billion)
Figure 32. United Arab Emirates: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021– 2031 (US$ Billion)
Figure 33. Rest of Middle East & Africa: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021– 2031 (US$ Billion)
Figure 1. Middle East & Africa Generic Drugs Market Segmentation – Country
Figure 2. PEST Analysis
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Middle East & Africa Generic Drugs Market Revenue (US$ Billion), 2021–2031
Figure 5. Middle East & Africa Generic Drugs Market Share (%) – by Molecule Type (2024 and 2031)
Figure 6. Antidepressants: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 7. Antihistamines: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 8. Analgesics: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 9. Antibiotics: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 10. Antivirals: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 11. Diuretics: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 12. Others: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 13. Middle East & Africa Generic Drugs Market Share (%) – by Indication (2024 and 2031)
Figure 14. Metabolic Diseases: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 15. Cancer: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 16. Immunology: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 17. Respiratory Disorder: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 18. Cardiovascular Disorder: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 19. Neurology Disorder: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 20. Rare Disease: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 21. Others: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 22. Middle East & Africa Generic Drugs Market Share (%) – by Type (2024 and 2031)
Figure 23. Prescription: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 24. OTC Drugs: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 25. Middle East & Africa Generic Drugs Market Share (%) – by Distribution Channel (2024 and 2031)
Figure 26. Hospital Pharmacies: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 27. Retail Pharmacies: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 28. Online Pharmacies: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 29. Middle East & Africa Generic Drugs Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 30. Saudi Arabia: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021– 2031 (US$ Billion)
Figure 31. South Africa: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021– 2031 (US$ Billion)
Figure 32. United Arab Emirates: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021– 2031 (US$ Billion)
Figure 33. Rest of Middle East & Africa: Middle East & Africa Generic Drugs Market – Revenue and Forecast, 2021– 2031 (US$ Billion)
